Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-07-26

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00123851

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer

Phase 2

Conditions: Rectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-07-22

Last Posted Date: 2012-01-19

Lead Sponsor: Alberta Health services

Target Recruit Count: 66

Registration Number: NCT00122291

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Methotrexate

First Posted Date: 2005-07-21

Last Posted Date: 2013-12-24

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 164

Registration Number: NCT00121134

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: vorinostat

First Posted Date: 2005-07-21

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 28

Registration Number: NCT00121277

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2005-07-21

Last Posted Date: 2011-04-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 109

Registration Number: NCT00121836

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Gemcitabine Hydrochloride
Drug: Sorafenib Tosylate

First Posted Date: 2005-07-21

Last Posted Date: 2021-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00121251

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

and more 1 locations

Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor Cancer

First Posted Date: 2005-07-13

Last Posted Date: 2008-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00119171

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Phase 2

Withdrawn

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2005-07-13

Last Posted Date: 2015-05-27

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Registration Number: NCT00119314

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Hematology and Oncology Group, Somerset, New Jersey, United States

and more 3 locations

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: Oxaliplatin
Drug: bevacizumab

First Posted Date: 2005-07-12

Last Posted Date: 2011-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 435

Registration Number: NCT00118755

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Biological: bevacizumab
Drug: capecitabine
Drug: oxaliplatin
Procedure: conventional surgery

First Posted Date: 2005-07-11

Last Posted Date: 2013-01-03

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00118105

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸
Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States

and more 43 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy